Patents Assigned to AstraZeneca
  • Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders
    Publication number: 20080255085
    Abstract: Compounds of formula I wherein X is or Y; and wherein A, Y, R1, R2, R3, R4 and R5 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: October 2, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Per I Arvidsson, Erwan Arzel, Jeremy Burrows, Martina Claesson, Colin Ray, Tobias Rein, Didier Rotticci, Peter Soderman
  • Novel 2-Aminopyrimidinone Derivatives And Their Use
    Publication number: 20080255164
    Abstract: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 13, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jeffrey Albert, Donald Andisik, Phil Edwards, Mark Sylvester
  • Formulation
    Publication number: 20080248077
    Abstract: The present invention relates to slow release anastrozole formulations, more particularly to biodegradable polymers, typically a polylactide or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated, including microparticle formulations and monolithic implant formulations. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer.
    Type: Application
    Filed: August 29, 2006
    Publication date: October 9, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Paul Richard Gellert, Balvinder Singh Matharu
  • Interleukin-13 Antibody Composition
    Publication number: 20080248048
    Abstract: The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and Hodgkin's lymphoma, particularly asthma.
    Type: Application
    Filed: September 29, 2006
    Publication date: October 9, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Brendan Cormick Fish, Jeanette Elizabeth Langstone, Karen Bannister, Claire Louise Hope
  • Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
    Publication number: 20080249086
    Abstract: There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: February 11, 2008
    Publication date: October 9, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Annika Bjore, Ulrik Gran, Gert Strandlund
  • Pyrrole-2,5-dione derivatives as Liver X receptor modulators
    Patent number: 7432288
    Abstract: The present invention relates to certain novel compounds of the Formula I to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR)?(NR1H3) and/or ?(NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: October 7, 2008
    Assignee: AstraZeneca AB
    Inventors: Jonas Boström, Kay Brickmann, Patrik Holm, Pernilla Sandberg, Marianne Swanson, Christer Westerlund
  • NOVEL PYRIMIDINE DERIVATIVES 698
    Publication number: 20080242663
    Abstract: The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof, where R1, n, R2, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.
    Type: Application
    Filed: February 28, 2008
    Publication date: October 2, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Susan Elizabeth Ashton, Darren Anthony Edward Cross, Simon John East, Jason Grant Kettle, Mark Andrew Pearson, Stephen Robert Wedge, Bernard Christophe Barlaam, Richard Ducray, Stuart Charles Purkiss
  • New Method 706
    Publication number: 20080242590
    Abstract: The present invention relates fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein has the formula M-A, capable of degrading amyloid beta peptide at one or more cleavage sites in its amino acid sequence, wherein M is a protein component that prolongs the half-life of the fusion protein, and A is a protein component that cleaves the amyloid beta peptide.
    Type: Application
    Filed: March 28, 2008
    Publication date: October 2, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Christin Andersson, Per-Ola Freskgard
  • Method 741
    Publication number: 20080242688
    Abstract: Methods of treatment and pharmaceutical compositions for providing improved cognition in subjects suffering from schizophrenia, Alzheimer's disease or other conditions with impaired cognitive function.
    Type: Application
    Filed: March 17, 2008
    Publication date: October 2, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Stacy A. Castner, Thomas Hudzik, Donna L. Maier, Ladislav Mrzljak, Timothy Piser, Jeff S. Smith, Dan Widzowski, Graham V. Williams
  • Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
    Patent number: 7429675
    Abstract: The present invention provides a process for the preparation of substantially racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid which comprises reacting 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid enriched in one enantiomer with a base in an inert solvent.
    Type: Grant
    Filed: June 16, 2004
    Date of Patent: September 30, 2008
    Assignee: AstraZeneca AB
    Inventors: Eva-Lotte Lindstedt-Alstermark, Kjell Andersson, Henrik Sorensen
  • 2-(Arylalkoxy)-1-Phenylethylamine Derivatives As NK1 Antagonist And Serotonin Reuptake Inhibitors
    Publication number: 20080234282
    Abstract: Compounds of the following formula (I) wherein R1R2, n, Ar1 and A2 are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The example compounds are 1-(2-(naphthylmethoxy)-1-phenylethyl)piperazine derivatives. The compounds are neurokinin 1 (NK1) receptor antagonist and/or serotonin reuptake inhibitors, with medical indications for depression and other disorders.
    Type: Application
    Filed: March 21, 2008
    Publication date: September 25, 2008
    Applicant: ASTRAZENECA AB
    Inventor: Cathy Dantzman
  • Novel triazolo pyrimidine compounds
    Publication number: 20080234481
    Abstract: The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.
    Type: Application
    Filed: April 28, 2008
    Publication date: September 25, 2008
    Applicant: AstraZeneca AB
    Inventors: Ulf Larsson, Mattias Magnusson, Tibor Musil, Andreas Palmgren
  • N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands
    Publication number: 20080234269
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: September 19, 2006
    Publication date: September 25, 2008
    Applicant: ASTRAZENECA AB
    Inventors: James B. Campbell, Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li
  • Novel Compounds
    Publication number: 20080234274
    Abstract: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors.
    Type: Application
    Filed: June 3, 2008
    Publication date: September 25, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Andrew Bailey, Garry Pairaudeau, Anil Patel, Stephen Thom
  • Metalloproteinase inhibitors
    Patent number: 7427631
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: September 23, 2008
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
    Patent number: 7427626
    Abstract: Compounds of the formula (I), and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti cell proliferation) effect in a warm blooded animal, such as man.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: September 23, 2008
    Assignee: AstraZeneca AB
    Inventor: Andrew Peter Thomas
  • Condensed pyridines and pyrimidines with tie2 (TEK) activity
    Patent number: 7427616
    Abstract: A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I): G is selected from O, S and NR5; Z is selected from N and CR6; Q1 is selected from optionally substituted aryl and heteroaryl, and the substituents R1 to R6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: September 23, 2008
    Assignee: AstraZeneca AB
    Inventors: Richard William Arthur Luke, Clifford David Jones, William McCoull, Barry Raymond Hayter
  • 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders
    Publication number: 20080227824
    Abstract: The present invention is directed to novel compounds of formula (I)/(II)/(III), their use in therapy and pharmaceutical compositions comprising said novel compounds.
    Type: Application
    Filed: September 20, 2006
    Publication date: September 18, 2008
    Applicant: Astrazeneca AB
    Inventors: Alexander Minidis, David Wensbo, Abdelmalik Slassi, Methvin Isaac, Caroline Ericsson, Veronica Profir, Per-Olov Bergstrom, Louise Edwards, Jalaj Arora, Tao Xin
  • Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases
    Publication number: 20080227797
    Abstract: The present invention provides a compound of a formula (I): [Chemical formula should be inserted here. Please see paper copy] wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.
    Type: Application
    Filed: July 3, 2006
    Publication date: September 18, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Annea Lisius, Grigorios Nikitidis, Peter Sjo
  • Container device
    Patent number: D578302
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: October 14, 2008
    Assignee: AstraZeneca AB
    Inventors: Lars Arvidsson, Lena Axelson-Larsson, Per Frid